
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that, at a meeting of the Board of Directors held today, it...
Read more about Astellas Announces Transition to a Company with an Audit & Supervisory Committee
(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and...
Read more about Astellas Announces Acquisition of Own Shares
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company” ) today announced that its Board of Directors approved a change in its...
Read more about Astellas Appoints Kenji Yasukawa as President and CEO
TOKYO – January 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data to be presented at the 2018 Genitourinary Cancers...
Tokyo, Janurary 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Mitobridge, Inc....
Read more about Astellas Completes Acquisition of Mitobridge, Inc.